ReviewCardiovascular toxicology2026
Reduced ALDH2 Activity and Cardiovascular Carbonyl Stress: From Reactive Aldehyde Networks to Coronary Microvascular Obstruction.
Review in Cardiovascular toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Primary percutaneous coronary intervention restores epicardial flow after ST-segment elevation myocardial infarction, but tissue perfusion may remain impaired. Coronary microvascular dysfunction, angiographic no-reflow, cardiac magnetic resonance-defined microvascular obstruction, and intramyocardial hemorrhage are overlapping but non-equivalent phenotypes. This review examines reduced mitochondrial aldehyde dehydrogenase 2 (ALDH2) activity as a susceptibility amplifier rather than an established independent cause of these outcomes. Reperfusion generates reactive oxygen species that initiate lipid peroxidation and produce electrophilic aldehydes, including 4-hydroxy-2-nonenal, malondialdehyde, and acrolein. Their effects are shaped by compartmental generation, competing clearance systems, protein-adduct persistence, and positive feedback between mitochondrial injury and inflammation. Methylglyoxal is considered a parallel, glyoxalase-dominant dicarbonyl pathway rather than a principal ALDH2 substrate. The resulting network may impair endothelial nitric oxide signaling and barrier integrity, promote platelet activation and neutrophil extracellular trap formation, and increase cardiomyocyte edema and damage-associated molecular-pattern release. Pericyte constriction contributes to experimental no-reflow, whereas pericyte sensitivity to 4-hydroxy-2-nonenal remains a theoretical hypothesis awaiting direct experimental confirmation. We also assess adductomics, proteomics, lipidomics, and time-resolved sampling strategies. Free aldehydes are chemically and preanalytically unstable; protein-bound adducts provide longer detection windows but lack the clinical standardization of cardiac troponin. ALDH2 activation remains preclinical for reperfusion microvascular injury. Prospective studies should further integrate genotype, enzyme activity, local carbonyl measurements, thromboinflammatory phenotyping, invasive physiology, and cardiac magnetic resonance endpoints.
Indexed as
Identifiers
42799865What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.